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Eur J Vasc Endovasc Surg (2015) 49, 621e622EDITORIALDual Antiplatelet Therapy after Carotid Stenting: Lessons from ‘Big Brother’Although it is accepted that carotid artery stent (CAS) pa-
tients should receive dual antiplatelet therapy (currently
aspirin and clopidogrel) throughout the perioperative
period in order to minimize the risks of acute stent
thrombosis/embolization secondary to platelet activation
triggered by intimal injury and/or the insertion of a foreign
body (stent), there is no evidence-based consensus as to
how long dual antiplatelet therapy (DAPT) should continue
thereafter.
International guidelines provide inconsistent advice
regarding the optimal duration of dual antiplatelet therapy
after CAS, ranging from “at least 30 days” (American Heart
Association [AHA], Society for Vascular Surgery [SVS]1,2 to 3
months [European Society of Vascular Surgery]).3 None of
the guidelines recommended long-term or lifelong dual
antiplatelet therapy after CAS; all recommended life-long
aspirin therapy following discontinuation of clopidogrel,
and there were no recommendations regarding the role of
the newer generation antiplatelet agents.1,4
It is, however, not unusual for the ﬁndings of cardiology
based research to be extrapolated into other cardiovascular
interventional practices whenever data are “missing”. The
decision to recommend that CAS be undertaken using
periprocedural dual antiplatelet therapy was, for example,
the product of research following coronary stenting, which
showed lower rates of in-stent thrombosis and acute cor-
onary events than antiplatelet monotherapy. Thereafter,
remaining debate concerned for how long DAPT should
continue. For some time now, it has been advised that
patients undergoing coronary interventions using drug-
eluting stents (DESs) should maintain DAPT for 6e12
months. However, the 2014 ESC guidelines on myocardial
revascularization recommend that DAPT should stop after 6
months in patients receiving the latest generation DESs
(possibly even at 3 months) on the basis that bleeding risks
increase if DAPT extends to 12 months and because of a
lack of evidence regarding any potential beneﬁt in terms of
preventing late ischemic myocardial complications.5 How-
ever, notwithstanding the fact that the 2014 ESC guidelines
now recommend a shorter duration of DAPT, some of our
cardiology colleagues are back to debating about whether
DAPT should be extended beyond 12 months.6
The Dual Antiplatelet Therapy (DAPT) study was a large
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http://dx.doi.org/10.1016/j.ejvs.2015.02.004to determine the beneﬁts/risks of extending dual anti-
platelet therapy beyond 12 months in patients who had
received coronary stents.6 In this study, 9961 patients who
had completed 12 months of dual antiplatelet therapy after
implantation of a DES were randomly assigned to an addi-
tional 18 months of thienopyridine therapy (clopidogrel or
prasugrel) versus placebo. All patients continued to take
aspirin. The main ﬁnding was that extending clopidogrel or
prasugrel to 30 months signiﬁcantly reduced the relative
risk of suffering a major adverse cardiovascular and/or ce-
rebrovascular event by 29% (absolute risk 4.3% vs. 5.9%,
p < .001). The overall reduction in major cardiovascular
events at 30 months was more evident in patients taking
prasugrel. Of relevance, the reduction in major vascular
events was not strictly related to the prevention of coronary
DES thrombosis. Continued thienopyridine therapy was
associated with both a lower cumulative incidence of stent
thrombosis (0.4% vs. 1.4%; hazard ratio 0.29; 95% CI 0.17e
0.48; p < .001) and of myocardial infarction than with
placebo (2.1% vs. 4.1%; hazard ratio 0.47; 95% CI 0.37 to
0.61; p < .001). Myocardial infarctions that were not
related to stent thrombosis (1.8% vs. 2.9%; hazard ratio
0.59; p < .001) accounted for 55% of the events, suggesting
a beneﬁcial effect for prolonged DAPT outside the coronary
stented area. In addition, and of greater practical relevance
regarding the debate in CAS patients, the DAPT trial
included 1687 patients who had a bare-metal stent inserted
into their coronary circulation. In these patients, a subgroup
analysis showed that continued thienopyridine therapy may
confer a relative risk reduction of 51% in late stent
thrombosis at 30 months (AHA oral communication).
What about adverse events related to prolonged dual
antiplatelet therapy? Perhaps not unsurprisingly, the inci-
dence of moderate/severe bleeding was increased in pa-
tients randomized to extended thienopyridine treatment
(2.5% vs. 1.6%, p ¼ .001).6 However, an unexpected ﬁnding
(albeit with borderline statistical signiﬁcance) was an in-
crease in late mortality in patients randomized to extended
thienopyridine therapy (2.0% vs. 1.5%, hazard ratio 1.36,
p ¼ .05) that may have been due, at least in part, to an
imbalance in pre-existing cancer (and subsequently in
cancer-related mortality) in patients randomized to
extended clopidogrel/prasugrel (0.62% vs. 0.28%, p ¼ .02).
This increase in late mortality was not attributable to excess
cardiovascular, hemorrhagic or trauma-related events, and
when cancer-related deaths were excluded from analysis
there was no signiﬁcant difference in late survival.
622 EditorialSubsequent data from post-marketing studies that had
contributed to the DAPT trial also showed an alarming
rebound in cardiovascular events in the ﬁrst 3 months after
stopping clopidogrel/prasugrel at either 12 or 30 months.6
Previous studies have also shown a possible causal rela-
tionship between the recovery of platelet reactivity
following cessation of thienopyridine therapy and a sus-
ceptibility towards increased cardiovascular events.7
At ﬁrst sight, therefore, the combination of reduced late
cardiovascular events, counterbalanced with an increase in
(non-cardiovascular) mortality could be interpreted as a
challenge to any beneﬁt from extending dual antiplatelet
therapy. It has also been reported that patients with
asymptomatic carotid disease who were revascularized and
then received long-term dual antiplatelet therapy had
reduced survival (47% vs. 40% at 5 years of median follow-
up).8 Accordingly, the risk of increased thrombotic events
following discontinuation of DAPT raises the recurring
question of whether it is ever safe to discontinue dual an-
tiplatelet therapy in carotid stented patients.
It is hard, therefore, to know just how much of the DAPT
study data can be extrapolated to help manage CAS pa-
tients. However, the observation that patients with bare-
metal coronary stents who were randomized to extended
thienopyridine therapy suffered fewer major cardiovascular
events suggests that the mid-term beneﬁt conferred by
DAPT may not be exclusive to DESs. It remains to be seen
whether a similar phenomenon happens following cessation
of dual antiplatelet therapy in CAS patients at 3 months (or
whenever it is stopped). Few non-randomized studies have
reported outcome data at this time-point and none of the
randomized trials has reported whether the time line for
recurrent stroke is higher in the ﬁrst few weeks/months
after cessation of dual antiplatelet therapy. This is surely a
question that could be answered relatively easily and which
could have a major impact in determining whether CAS
patients face a similarly high risk of rebound thromboem-
bolic stroke following cessation of DAPT. If they do not, then
it would seem reasonable to stop DAPT after 3 months (as is
current practice). If there is, however, evidence of an
increased risk of stroke following cessation of DAPT,
currently accepted guidelines of practice may need to be
changed.
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